AI Investing Insights - Official Homepage

News

4.0

01-19aastocks

G Sachs Updates Ratings and Price Targets for Chinese Gaming and Entertainment Stocks (Table)

4.5

01-15aastocks

HSI Falls 147 Points at Midday as TRIP.COM-S Plummets Nearly 20%; NEW WORLD DEV Rises 12%

2.0

01-14aastocks

BABA-W's Qianwen Surpasses 100M MAUs; Significant Product Update Expected Tomorrow: Report

4.0

2025-12-02aastocks

Citi Releases Ratings and Target Prices for Chinese Internet Companies (Table)

6.5

2025-11-27aastocks

Galaxy Securities Suggests POP MART as a Top Pick in Trendy Toy Market, Anticipates Continued National Subsidies from CN Next Year to Stimulate Consumption

Money Flow

Over the past 66 trading days, overall net money flow is 15.69M, with retail investors contributing 12.73M and major investors adding -10.14M.

Net Buy $ Volume

Net Sell $ Volume

Goldman Sachs

Buy

maintain

2025-11-19

Reason

The analyst rating from Goldman Sachs is maintained as a "Buy" despite a reduction in the target price from HKD 1.3 to HKD 1.17. The reasoning behind this rating includes the solid results reported by DAMAI ENT for 1HFY26 and the expectation that the company's expansion of licensing resources, particularly from Sanrio into retail and consumer markets, will drive strong growth in the next 6-12 months. However, concerns about the slowdown in the domestic ticketing business, increased investments in international markets, and the company's reliance on Japanese intellectual property amid Sino-Japanese tensions have contributed to stock price volatility.

Goldman Sachs

Buy

Price Target

2025-11-19

maintain

The analyst rating from Goldman Sachs is maintained as a "Buy" despite a reduction in the target price from HKD 1.3 to HKD 1.17. The reasoning behind this rating includes the solid results reported by DAMAI ENT for 1HFY26 and the expectation that the company's expansion of licensing resources, particularly from Sanrio into retail and consumer markets, will drive strong growth in the next 6-12 months. However, concerns about the slowdown in the domestic ticketing business, increased investments in international markets, and the company's reliance on Japanese intellectual property amid Sino-Japanese tensions have contributed to stock price volatility.

Citi

maintain

2025-11-18

Reason

The analyst rating from Citi is based on the assessment that the delay of the two Japanese films will have a very limited negative impact on China's overall box office, as Japanese films contributed only 5% to the box office last year. The primary concern is related to market sentiment and investor worries about potential risks to MAOYAN ENT, particularly regarding the possible suspension of its key film "Demon Slayer" if geopolitical tensions escalate. Despite the negative sentiment surrounding the involvement of Japanese IP, the actual impact on DAMAI ENT is expected to be minimal. Consequently, Citi has set target prices for DAMAI ENT at HKD1.4 and for MAOYAN ENT at HKD9.3.

Citi

Price Target

2025-11-18

maintain

The analyst rating from Citi is based on the assessment that the delay of the two Japanese films will have a very limited negative impact on China's overall box office, as Japanese films contributed only 5% to the box office last year. The primary concern is related to market sentiment and investor worries about potential risks to MAOYAN ENT, particularly regarding the possible suspension of its key film "Demon Slayer" if geopolitical tensions escalate. Despite the negative sentiment surrounding the involvement of Japanese IP, the actual impact on DAMAI ENT is expected to be minimal. Consequently, Citi has set target prices for DAMAI ENT at HKD1.4 and for MAOYAN ENT at HKD9.3.

Jefferies

maintain

$1.4

2025-11-07

Reason

The analyst rating for DAMAI ENT (01060.HK) is maintained at "Buy" with a target price of HKD1.4 due to a positive profit alert for 1HFY26, where estimated earnings are expected to exceed RMB500 million, surpassing both market and Jefferies' forecasts. This growth is attributed to the strong performance of Alifish and a year-over-year reduction in investment losses, aided by an improved asset structure. Additionally, Jefferies anticipates that investment losses will decrease in 1HFY26, contributing to the better-than-expected results.

Jefferies

Price Target

$1.4

2025-11-07

maintain

The analyst rating for DAMAI ENT (01060.HK) is maintained at "Buy" with a target price of HKD1.4 due to a positive profit alert for 1HFY26, where estimated earnings are expected to exceed RMB500 million, surpassing both market and Jefferies' forecasts. This growth is attributed to the strong performance of Alifish and a year-over-year reduction in investment losses, aided by an improved asset structure. Additionally, Jefferies anticipates that investment losses will decrease in 1HFY26, contributing to the better-than-expected results.

CICC

Buy

maintain

$1.32

2025-11-07

Reason

The analyst rating for DAMAI ENT (01060.HK) is positive due to the company's issuance of a profit alert indicating a significant expected increase in net profit for 1HFY2026, projected to be no less than RMB500 million, which represents a year-on-year growth of approximately 48%. This positive outlook is attributed to the strong performance of the Alifish business, which has shown robust revenue and profit growth. Additionally, the presence of popular intellectual properties (IPs) such as Sanrio, Chiikawa, and Crayon Shin-chan is seen as a key driver of current revenue and profit. CICC has maintained its full-year revenue and profit forecasts for the company and has set a target price that implies a 40% upside from the current stock price, further supporting the positive rating.

CICC

Buy

Price Target

$1.32

2025-11-07

maintain

The analyst rating for DAMAI ENT (01060.HK) is positive due to the company's issuance of a profit alert indicating a significant expected increase in net profit for 1HFY2026, projected to be no less than RMB500 million, which represents a year-on-year growth of approximately 48%. This positive outlook is attributed to the strong performance of the Alifish business, which has shown robust revenue and profit growth. Additionally, the presence of popular intellectual properties (IPs) such as Sanrio, Chiikawa, and Crayon Shin-chan is seen as a key driver of current revenue and profit. CICC has maintained its full-year revenue and profit forecasts for the company and has set a target price that implies a 40% upside from the current stock price, further supporting the positive rating.

CICC

Buy

maintain

$1.32

2025-11-07

Reason

The analyst rating for DAMAI ENT (01060.HK) is positive due to the company's issuance of a profit alert indicating a significant expected increase in net profit for 1HFY2026, projected to be no less than RMB500 million, which represents a year-on-year growth of approximately 48%. This positive outlook is attributed to the strong performance of the Alifish business, which has shown robust revenue and profit growth. Additionally, the presence of popular intellectual properties (IPs) such as Sanrio, Chiikawa, and Crayon Shin-chan is expected to continue driving revenue and profit. CICC maintained its revenue and profit forecasts for the company and set a target price that implies a 40% upside from the current stock price, further supporting the positive rating.

CICC

Buy

Price Target

$1.32

2025-11-07

maintain

The analyst rating for DAMAI ENT (01060.HK) is positive due to the company's issuance of a profit alert indicating a significant expected increase in net profit for 1HFY2026, projected to be no less than RMB500 million, which represents a year-on-year growth of approximately 48%. This positive outlook is attributed to the strong performance of the Alifish business, which has shown robust revenue and profit growth. Additionally, the presence of popular intellectual properties (IPs) such as Sanrio, Chiikawa, and Crayon Shin-chan is expected to continue driving revenue and profit. CICC maintained its revenue and profit forecasts for the company and set a target price that implies a 40% upside from the current stock price, further supporting the positive rating.

Goldman Sachs

maintain

$1.3

2025-11-07

Reason

The analyst rating for DAMAI ENT was maintained at "Buy" due to the company's positive profit alert for 1HFY2026, projecting a net profit attributable to shareholders of no less than RMB500 million, which exceeds Goldman Sachs' forecast by 7%. The significant growth in net profit is attributed to strong year-over-year growth in the Alifish business and a reduction in investment losses compared to the previous year. The broker set a 12-month target price of $1.3 based on the sum-of-the-parts (SOTP) valuation method.

Goldman Sachs

Price Target

$1.3

2025-11-07

maintain

The analyst rating for DAMAI ENT was maintained at "Buy" due to the company's positive profit alert for 1HFY2026, projecting a net profit attributable to shareholders of no less than RMB500 million, which exceeds Goldman Sachs' forecast by 7%. The significant growth in net profit is attributed to strong year-over-year growth in the Alifish business and a reduction in investment losses compared to the previous year. The broker set a 12-month target price of $1.3 based on the sum-of-the-parts (SOTP) valuation method.

Valuation Metrics

Forward PE

N/A

5Y Average PE

13.92

Current PE

23.01

Overvalued PE

91.92

Undervalued PE

-64.08

Forward EV/EBITDA

5Y Average EV/EBITDA

19.14

Current EV/EBITDA

15.96

Overvalued EV/EBITDA

33.82

Undervalued EV/EBITDA

4.45

Forward PS

5Y Average PS

3.20

Current PS

2.83

Overvalued PS

4.66

Undervalued PS

1.73

Financials

AI Analysis

Annual

Quarterly

Trading Trends

Daily

Monthly

No data

Short Selling

People Also Watch